Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis.
antipsychotics
depression
dysthymia
schizofrenia
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
04
03
2021
accepted:
15
05
2021
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
16
3
2022
Statut:
ppublish
Résumé
Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder. We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and ProQuest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A random-effect meta-analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability. We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD] = -0.70, CI 95% -0.92, -0.49; I Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.
Sections du résumé
BACKGROUND
Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder.
METHODS
We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and ProQuest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A random-effect meta-analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability.
RESULTS
We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD] = -0.70, CI 95% -0.92, -0.49; I
CONCLUSION
Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.
Identifiants
pubmed: 34727399
doi: 10.1002/hup.2801
pmc: PMC8596405
doi:
Substances chimiques
Antipsychotic Agents
0
Amisulpride
8110R61I4U
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2801Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons Ltd.
Références
J Affect Disord. 1997 Apr;43(2):95-103
pubmed: 9165379
Int J Law Psychiatry. 2017 Nov - Dec;55:64-71
pubmed: 29157513
Arch Gen Psychiatry. 2011 Jan;68(1):90-100
pubmed: 21199968
BMC Psychiatry. 2019 Dec 13;19(1):396
pubmed: 31836015
Arch Gen Psychiatry. 1992 Oct;49(10):817-23
pubmed: 1417435
World J Biol Psychiatry. 2013 Aug;14(6):412-31
pubmed: 23530731
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Tijdschr Psychiatr. 2008;50(8):519-28
pubmed: 18688776
Depress Anxiety. 2014 Aug;31(8):621-30
pubmed: 24448972
J Family Med Prim Care. 2017 Apr-Jun;6(2):243-248
pubmed: 29302525
J Affect Disord. 1998 Feb;48(1):47-56
pubmed: 9495601
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1504-9
pubmed: 17692448
Psychopharmacology (Berl). 2009 Jul;205(1):119-28
pubmed: 19337725
Schizophr Res. 2005 Sep 1;77(1):11-24
pubmed: 16005381
Int Clin Psychopharmacol. 2002 Jan;17(1):27-32
pubmed: 11800503
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Clin Psychol Psychother. 2018 May;25(3):457-464
pubmed: 29493054
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
CNS Drugs. 2012 Feb 1;26(2):135-53
pubmed: 22296316
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Eur Psychiatry. 2006 Dec;21(8):523-30
pubmed: 17113759
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):733-9
pubmed: 23703492
Patient Prefer Adherence. 2012;6:369-88
pubmed: 22654508
Hum Psychopharmacol. 2021 Nov;36(6):e2801
pubmed: 34727399
Int Clin Psychopharmacol. 2002 Dec;17 Suppl 4:S9-15; discussion S16-7
pubmed: 12685917
Eur Neuropsychopharmacol. 2020 Dec;41:16-27
pubmed: 33077324
PLoS One. 2016 May 17;11(5):e0153380
pubmed: 27187783
J Affect Disord. 2002 Aug;70(3):313-7
pubmed: 12128243
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Psychiatry Res. 2017 Apr;250:50-58
pubmed: 28142066
Neuropsychobiology. 1999;39(1):25-32
pubmed: 9892856
Arch Gen Psychiatry. 1994 May;51(5):365-74
pubmed: 8179460
Psychol Rep. 1992 Aug;71(1):208-10
pubmed: 1529057
Mol Psychiatry. 2002;7(3):247-53
pubmed: 11920152
Compr Psychiatry. 2000 Mar-Apr;41(2 Suppl 1):39-47
pubmed: 10746903
Eur J Pharmacol. 2013 Nov 5;719(1-3):25-33
pubmed: 23872400
Psychiatr Danub. 2019 Jun;31(2):148-156
pubmed: 31291218
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD008121
pubmed: 21154393
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Expert Opin Pharmacother. 2007 Aug;8(11):1693-710
pubmed: 17685886
Psychiatry Res. 2002 Oct 10;112(2):145-52
pubmed: 12429360
J Gen Intern Med. 2007 Jun;22(6):711-8
pubmed: 17503104
Int Clin Psychopharmacol. 2001 Nov;16(6):317-24
pubmed: 11712619
Hum Psychopharmacol. 2002 Jan;17(1):1-13
pubmed: 12404702
CNS Drugs. 2004;18(13):933-56
pubmed: 15521794
JAMA. 2013 Aug 14;310(6):591-608
pubmed: 23842577
J Psychopharmacol. 1999;13(3):248-54
pubmed: 10512080
Am J Psychiatry. 1996 Nov;153(11):1411-7
pubmed: 8890673
Support Care Cancer. 2007 May;15(5):539-46
pubmed: 17406919